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Abstract
Adhesion inhibitors that block the attachment of pathogens to host tissues may be used synergistically with or as an
alternative to antibiotics. The wide-spread bacterial adhesin Multivalent Adhesion Molecule (MAM) 7 has recently
emerged as a candidate molecule for a broad-spectrum adhesion inhibitor which may be used to prevent bacterial
colonization of wounds. Here we have tested if the antibacterial properties of a MAM-based inhibitor could be used to
competitively inhibit adhesion of methicillin-resistant Staphylococcus aureus (MRSA) to host cells. Additionally, we
analyzed its effect on host cellular functions linked to the host receptor fibronectin, such as migration, adhesion and
matrix formation in vitro, to evaluate potential side effects prior to advancing our studies to in vivo infection models.
As controls, we used inhibitors based on well-characterized bacterial adhesin-derived peptides from F1 and FnBPA,
which are known to affect host cellular functions. Inhibitors based on F1 or FnBPA blocked MRSA attachment but at
the same time abrogated important cellular functions. A MAM7-based inhibitor did not interfere with host cell function
while showing good efficacy against MRSA adhesion in a tissue culture model. These observations provide a
possible candidate for a bacterial adhesion inhibitor that does not cause adverse effects on host cells while
preventing bacterial infection.
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Introduction
Wound infections are increasingly challenging to treat due to
a rise in multidrug-resistant (MDR) bacterial isolates. While
MDR Gram-negative bacteria such as Klebsiella pneumoniae
and Pseudomonas aeruginosa increasingly contribute to the
profile of wound infections seen in the clinic, Gram-positives
and above all methicillin-resistant Staphylococcus aureus
(MRSA) remain a major cause of morbidity and mortality in
wounded patients [1,2]. As an alternative approach to
antimicrobial treatment of wound infections, we are studying
the potential of targeting bacterial-host interactions using
adhesion inhibitors. Prevention of bacterial attachment to host
tissues abrogates subsequent processes facilitating infection,
such as type III secretion system (T3SS)-mediated effector
injection into host cells or cellular invasion, making this a
promising strategy for management of bacterial infections [3].
S. aureus employ an array of adhesins to achieve host cell
attachment and invasion and exploits fibronectin as a key
receptor for cell attachment and invasion [4-6]. Attempts have
been made to utilize peptides derived from fibronectin-binding
proteins (FnBPs) as adhesion inhibitors[6,7]. For example, a
recombinant fragment of the S. aureus adhesin fibronectin-
binding protein A (FnBPA) diminished staphylococcal abscess
formation in a guinea pig model of wound infection and had a
synergistic effect on conventional antibiotic treatment [7].
However, the competitive properties of these molecules are
based on their ability to bind to the host receptor fibronectin
with high affinity. Since fibronectin is tightly involved in a range
of cellular processes prerequisite to wound healing, such as
cellular proliferation, adhesion, migration and matrix formation
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[8], this caused undesired side-effects on host cellular functions
[9,10].
We have recently identified a novel family of bacterial
adhesins, termed Multivalent Adhesion Molecules (MAMs).
MAMs are involved in initial bacterial attachment to host cells
and MAM homologs are found in many Gram-negative
pathogens [11]. MAMs are outer membrane proteins consisting
of tandem arrays of six to seven mammalian cell entry (mce)
domains. The mce domains mediate attachment to host tissues
by high affinity interaction with the host membrane lipid
phosphatidic acid (PA) and utilize fibronectin as a co-receptor
[12]. Since MAM homologs are present in many bacterial
species, the use of MAM-based inhibitors might be an
approach allowing prophylaxis and eventually treatment of a
broad spectrum of infections [13]. We have successfully used
inhibitors based on Vibrio parahaemolyticus MAM7 to prevent
infections caused by enteric pathogens in tissue culture
models, and more recently we demonstrated that this approach
can be extended to MDR Gram-negative isolates causing
wound infections [14].
Since the binding site in fibronectin recognized by MAM7 is
also recognized by S. aureus FnBPA, we set out to test if the
antibacterial properties of MAM7 could be extended to
competitively inhibit S. aureus adhesion to host cells.
Additionally, we analyzed the effects of a MAM7-based
adhesion inhibitor on host cellular responses in vitro, to
evaluate potential side effects prior to advancing our studies to
animal infection models. Along with a MAM7-based inhibitor,
we included in our study two other well-characterized adhesins
utilizing fibronectin as host receptor (Figure 1): The surface
protein F1 is a major adhesin of Streptococcus pyogenes, a
Gram-positive bacterium and an opportunistic pathogen
causing a spectrum of diseases, ranging from skin infections
and strep throat to toxic shock syndrome. F1 mediates tissue
colonization and invasion by binding to the N-terminal region of
Fn with nanomolar affinity [15,16]. The major fibronectin-
binding site in F1 is located to the functional upstream domain
(FUD), which encompasses the 43 residues of the F1 upstream
nonrepetitive domain and six residues of the first of five repeat
domains (Figure 1M), [9,17]. Previous studies suggested that
FUD binding to tissue may interfere with cellular functions such
as vascular remodeling [10].The second control peptide we
used was derived from S. aureus FnBPA, which had previously
been investigated as adhesion inhibitor [7]. FnBPA mediates
bacterial attachment and invasion of a variety of cell types by
attaching to the N-terminal region of fibronectin in a modular
fashion, using a tandem β-zipper mechanism [18-20]. FnBPA
contains eleven fibronectin-binding repeats (FnBRs) arranged
in tandem, and the binding affinity of individual repeats ranges
from 1nM to 3μM (Figure 1M), [21].
Our studies demonstrate that adhesion inhibitors based on
peptides derived from adhesins F1 and FnBPA efficiently block
bacterial adhesion but interfere with cellular processes
promoting wound healing, as was previously described. In
contrast, a MAM7-derived peptide is an effective adhesion
inhibitor but does not cause undesired effects on host cells in
vitro.
Materials and Methods
Cloning, expression and purification of bacterial
proteins
The MAM7-derived peptide contained residues 45-882 of
MAM7 (VP1611) and an N-terminal GST-tag. The F1-derived
peptide corresponds to F1 functional upstream domain (FUD),
as described previously [9]. Cloning, expression and
purification of MAM7 and F1 FUD peptides have been
described elsewhere [9,11]. The FnBPA-derived peptide
contained fibronectin-binding repeats 1-11 (FnBR1-11)
according to domain boundaries as described previously [21].
The construct containing FnBPA FnBR1-11 was amplified from
S. aureus USA300 genomic DNA and cloned into pGEX-TEV
using BamHI and NotI sites. Protein was expressed in E. coli
BL21 and purified on glutathione sepharose as previously
described for individual FnBRs [21].
Staphylococcus aureus adhesion to host cells
GST, MAM7, F1 or FnBPA derived peptides were
immobilized on latex beads as previously described [13]. Bead-
immobilized inhibitors in culture medium were added to plates
containing HeLa cells to give a final concentration of 500 nM
immobilized peptides and incubated for one hour. Medium was
then replaced with medium, containing GFP-expressing S.
aureus USA300 (gift from V. Torres lab) at a multiplicity of
infection of 10 and incubated for four hours. Cells were
washed, fixed with 3.2% formaldehyde, permeabilized with
0.5% Triton X-100 in PBS and stained for F-actin using
rhodamine-phalloidin and for nucleic acid using Hoechst 33342
as previously described [11]. Samples were imaged using a
fluorescence microscope and bacterial counts per cell were
determined by counting at least 15 images per sample. Images
were processed using Image J and Corel X5.
Analysis of MAM-inhibitor efficacy against enteric
infections
HeLa cells were infected with V. parahaemolyticus, V.
cholerae, Yersinia pseudotuberculosis or enteropathogenic E.
coli (EPEC) and cytotoxicity or actin pedestals/cell (for EPEC)
measured as previously described [11].
Scratch assays
HaCaT [22] and human dermal fibroblast (HDF) cell lines
[23] were a gift from the Hotchin lab (Univ. of Birmingham).
HaCaT, HDF and HeLa (ATCC number CRM-CCL-2) cells
were cultured in Dulbecco’s MEM supplemented with 10%
heat-inactivated fetal bovine serum (FBS) and 50 μg/ml
penicillin and streptomycin at 37°C with 5% CO2. Cells were
grown to a confluent monolayer which was scratched with a
pipette tip and washed with DMEM once. Cells were incubated
with fresh DMEM alone or containing 500 nM immobilized
GST, MAM7, F1 or FnBPA derived peptide and DIC images
were taken at t=0, 6, 12, 18 and 24 hours after scratching. Cell
migration into the cell-free gap and gap closure was evaluated
by measuring the gap between the two migrating fronts using
Adhesion Inhibition and Host Cell Function
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Image J and normalizing to the gap width at t=24 hours (100%
closure).
Analysis of peptide integrity
500 nM MAM7, F1 or FnBPA derived peptides in culture
medium was added to monolayers of fibroblasts and incubated
at 37°C. Supernatant samples were taken following 0, 6, 12, 18
and 24 hours of incubation and protein precipitated using TCA
precipitation. Samples were separated by SDS-PAGE and
amount of intact peptide was quantified using densitometry and
normalization to the peptide band from the sample taken at 0
hours.
Cell viability assays
Cells were seeded into 96-well plates at a density of 1.5·105
cells/ml one day prior to the experiment. Cultured cells were
incubated with DMEM alone or medium supplemented with 500
nM immobilized GST, MAM7, F1 or FnBPA peptides. Cell
viability after 4 hours and 24 hours of incubation was
determined by measuring lactate dehydrogenase (LDH) activity
in cell-free supernatants using an LDH Cytotoxicity Detection
Kit (Clontech) according to the manufacturer’s instructions.
Treatment with 1 μM staurosporine was used as a positive
control and results were normalized to total lysis controls (cells
lysed with 0.5 % Triton X-100, resulting in 100% cell death).
Cell proliferation assays
Cells were seeded into 96-well plates at a density of 1.5·105
cells/ml one day prior to the experiment. Proliferation of cells
grown in the absence or presence of 500 nM immobilized GST,
MAM7, F1 or FnBPA derived peptide for 24 hours was
measured using the CyQUANT NF Cell Proliferation Kit (Life
Technologies) according to the manufacturer’s instructions.
Cells grown in medium alone were used as a positive control
(100% proliferation) and for normalization.
Cell adhesion assays
Cell suspensions were prepared either in medium alone or
medium containing immobilized GST, MAM7, F1 or FnBPA
derived peptides, to give a final concentration of 1.5·105
cells/ml and 500 nM peptide. Experiments were carried out
both in the presence or absence of 10% fetal bovine serum.
Cells were seeded into 24-well plates and left in the incubator
to attach to the culture vessel for 2 or 12 hours, respectively.
Medium was removed and wells were washed three times with
PBS. Attached cells were removed using trypsin-EDTA and
Figure 1.  Adhesion inhibitors protect host cells from MRSA infection.  GST or peptides derived from MAM7, F1 and FnBPA
(blue arrows) were purified and immobilized on latex beads for inhibition experiments (M). HeLa cells incubated with MAM7-based
inhibitor (A-D and I-L) and infected with S. aureus USA300:GFP (E-L). DNA (blue, A, E, L), F-actin (red, B, F, J) and S. aureus
USA300:GFP (green, C, G, K) were visualized by fluorescence microscopy. Scale bar, 20 μm. S. aureus were counted after
infection in the presence of no inhibitor, NI or immobilized GST, CB, MAM7, F1 or FnBPA-peptide inhibitors (N). Results are means
± standard deviation from analyzing 15 randomly chosen images per sample, from experiments done in triplicate.
doi: 10.1371/journal.pone.0081216.g001
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counted using a hemocytometer. Attachment was normalized
to medium only control samples (100% attachment).
Matrix formation assays
Matrix formation was both visualized and quantified using the
incorporation of rhodamine-labelled fibronectin as reporter, as
described previously [9,24]. Briefly, fibronectin from human
plasma (Sigma) was prepared at 1 mg/ml in PBS and labeled
with a 10-fold molar excess of NHS-rhodamine for one hour at
22°C. Excess label was removed using desalting columns.
Fibroblasts were seeded at 2·105 cells/ml onto 6-wells
containing coverslips (for visualization) or 96-well plates (for
quantification) in the presence or absence of 500 nM
immobilized GST, MAM7, F1 or FnBPA derived peptides. After
one hour, rhodamine-fibronectin was added to a final
concentration of 20 nM and cells were incubated 12 or 24
hours, respectively. For visualization, cells were formaldehyde-
fixed, mounted and imaged using a fluorescence microscope
fitted with a 60x oil immersion lens. Images were processed
using Image J and Corel X5. Incorporation of labeled
fibronectin was quantified after 12 and 24 hours, respectively,
as described previously [24]. Controls were visualized
immediately to control for background fluorescence. Matrix
assembly was expressed as percentage and normalized to
medium control samples (100% assembly).
Results
Synthetic adhesion inhibitors based on MAM7, F1 and
FnBPA - derived peptides protect host cells from MRSA
adhesion
It was previously shown that prophylactic treatment with V.
parahaemolyticus MAM7-based adhesion inhibitors protects
host cells against subsequent infection with Gram-negative
pathogens in tissue culture models of infection. This is based
on competitive binding of the inhibitor to host cell receptors,
preventing pathogens from attaching [11]. Following our
previous work on MAM7-based adhesion inhibition of enteric
pathogens, we attempted to use recombinant purified MAM7
peptide, as well as a shorter peptide (MAM7 mce1 domain) as
inhibitors of infection with V. parahaemolyticus, V. cholerae,
Yersinia pseudotuberculosis or enteropathogenic E. coli
(EPEC) and found the efficacy of these to be significantly
lowered compared to that of MAM7-expressing non-pathogenic
bacteria. In contrast, when the longer (MAM7) peptide was
coupled to a polymer bead comparable in size to the bacteria
used, the inhibitory effect was fully restored (Figure S1).
Consequently, further adhesion inhibition studies were carried
out using bead-coupled MAM7 peptide.
We tested whether this synthetic MAM7-based inhibitor could
also be used to protect cells against Staphylococcus aureus, a
major causative agent of wound infections. We incubated HeLa
cells with GFP-expressing methicillin-resistant S. aureus
USA300, either with our without prior treatment with bead-
immobilized MAM7 peptide. MAM7-treated cells showed
significantly diminished S. aureus adhesion compared to
untreated controls (Figure 1).
We additionally used purified peptides derived from
Streptococcus pyogenes F1 (FUD, subsequently referred to as
F1 peptide) and S. aureus FnBPA (FnBR1-11, subsequently
referred to as FnBPA peptide) to see whether these proteins
could efficiently inhibit cellular attachment of S. aureus (Figure
1M). Both F1 and FnBPA peptides were immobilized to beads
and used to treat cells prior to incubation with S. aureus. While
S. aureus incubation of untreated host cells lead to bacterial
counts of approximately 46 bacteria per cell, pre-treatment with
either MAM7, F1 or FnBPA-based peptide inhibitors lead to a
decrease in bacterial counts to between one and three bacteria
per cell, while treatment with GST-immobilized control beads
did not significantly affect the number of host-associated
bacteria (Figure 1N).
F1 and FnBPA-based inhibitors, but not a MAM7-based
inhibitor, delay wound healing in scratch assays
Wound closure is a complex process, but scratch assays on
monolayers are often used to mimic wound healing in vitro and
to determine the influence of exogenous molecules on the
healing process in a simple model system. To test whether the
presence of adhesion inhibitors would influence wound healing
in vitro, we performed scratch assays and imaged scratched
monolayers of HaCaT, HDF and HeLa cells either immediately
or following a 24 hour period in the presence or absence of 500
nM immobilized GST, MAM7, F1 or FnBPA derived peptide
(Figure 2). In the absence of inhibitor, scratched layers of
HaCaT and HDF cells fully closed the scratch and HeLa cells,
which migrated slighty slower, almost closed the gap within 24
hours (Figure 2N). Similar results were obtained in the
presence of control beads (Figure 2C, I, O) or MAM7 inhibitor
(Figure 2D, J, P). In the presence of either F1 or FnBPA
inhibitors, scratch closure was compromised with all three cell
lines. While for HaCaT and HDF cells scratch closure was
decreased by approximately 50 % in the presence of either F1
or FnBPA inhibitors, healing was almost completely inhibited in
HeLa cells (Figure 2E, F, K, L, Q, R). The duration of all
experiments was limited to 24 hours and peptide integrity was
maintained over that period (Figure S2). To quantify the
inhibitory effects of bacterial peptides on scratch closure, we
determined the progress in scratch closure after 0, 6, 12, 18
and 24 hours of incubation (Figure 3). The results were in
agreement with those obtained from initial images: While
control beads or the MAM7 inhibitor had no significant effect on
scratch closure, both F1 and FnBPA inhibitors delayed healing
to a similar extent, with the inhibitory effect being most severe
on HeLa cells (Figure 3C).
Inadequate wound healing is not due to increased cell
death or decreased proliferation
Decreased rates of scratch closure could be due to
increased cell death or decreased proliferation of cells exposed
to adhesion inhibitors. To test whether the inhibitors increased
cell death, HaCaT, HDF and HeLa cells were grown in the
presence or absence of GST, MAM7, F1 or FnBPA inhibitors
for 4 hours or 24 hours, respectively, followed by
measurements of lactate dehydrogenase (LDH) activity in the
cell supernatant. Cell death causes an increase in membrane
Adhesion Inhibition and Host Cell Function
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permeability, which results in LDH release from cells into the
supernatant. As a total lysis control (100% cell death), cells
were lysed by addition of 0.5% Triton X-100. Neither of the four
immobilized peptides caused a significant increase in LDH
release from cells and thus cell death (Figure 4). Addition of 1
μM staurosporine (positive control), which causes cells to
undergo apoptotic cell death, killed close to 100% of cells in all
three cell lines within the same timeframe. Next, we tested if
attachment of adhesion inhibitors to host cells would cause a
decrease in proliferation rates. Cell lines were grown either with
or without prior addition of 500 nM GST, MAM7, F1 or FnBPA
inhibitors to the growth medium and proliferation was
determined after 24 hours using the CyQUANT NF Cell
Proliferation Kit. None of the four peptides caused a significant
change in cell proliferation compared to cells grown in medium
alone. Similar results were obtained for all three cell lines
tested (Figure 5).
Figure 2.  Effects of adhesion inhibitors on cellular migration.  Confluent layers of HaCaT (top), HDF (middle) or HeLa cells
(bottom) were scratched and imaged immediately (t=0h, A, G, M) or following 24 hours of incubation in medium alone (NI, B, H, N)
or medium containing 500 nM immobilized GST (CB, C, I, O), MAM7 (D, J, P), F1 (E, K, Q) or FnBPA peptides (F, L, R). Scale bar,
50 μm. Images are representative of a set of three experiments done in triplicate, with three frames taken per replicate. Images
were processed using Image J and Corel X5.
doi: 10.1371/journal.pone.0081216.g002
Figure 3.  Effects of adhesion inhibitors on the rate of scratch closure.  Experiments were performed as depicted in Figure 2
and scratch closure on confluent layers of HaCaT (A), HDF (B) or HeLa cells (C) was determined at t=0, 6, 12, 18 and 24 hours post
scratch. Scratch width at 24 hours post scratch was defined as 100 % closure. Results are means ± standard deviation from one of
a set of three experiments done in triplicate wells, with three frames taken per well. NI, no inhibitor present (open circles); CB, GST-
immobilized control beads (black circles), MAM7, bead-immobilized MAM7 peptide (open squares); F1, bead-immobilized FUD
peptide (closed triangles); FnBPA, bead-immobilized FnBPA (open triangles).
doi: 10.1371/journal.pone.0081216.g003
Adhesion Inhibition and Host Cell Function
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Adhesion inhibitors can cause decreased adhesion of
host cells
Cellular matrix adhesion is a prerequisite for migration and
thus wound healing. To test whether adhesion inhibitors could
influence the cells’ ability to adhere to a matrix, trypsin-treated
cells were washed and then seeded in culture vessels either in
the presence or absence of 500 nM GST, MAM7, F1 or FnBPA
based inhibitors, and the number of adherent cells was
determined using a hemocytometer, following either 2 hours or
12 hours of incubation. Cells in medium alone were used as a
positive control (NI, 100% adherence). Under serum-free
conditions, the adherence of all three cell types was
significantly decreased in the presence of either F1 or FnBPA
based inhibitors at both time points, while no measurable effect
was observed with control beads (Figure S3). The MAM7
inhibitor caused a slight decrease in adherence of HaCaT and
HeLa cells after 2 hours, but no significant differences were
observed after 12 hours of incubation or on HDF cells. To
better mimic in vivo conditions, the experiments were repeated
in medium containing 10% serum. Under these conditions, the
inhibitors’ ability to impair cellular adhesion to the substrate
was generally less pronounced. No significant differences in
HDF adherence were seen in the presence or absence of
inhibitors, with the exception of FnBPA after 2 hours (Figure
6B). However, a decrease in adherence of HaCaT and HeLa
cells in the presence of serum at both time points was
observed for cells plated with F1 and FnBPA inhibitors, (Figure
6A, C). No significant difference was observed with control
beads or MAM7 inhibitor at 2 hours with minor inhibition of
adherence observed with MAM7 inhibitor at 12 hours (Figure
6A, C).
F1 and FnBPA-based inhibitors, but not a MAM7-based
inhibitor, impair extracellular matrix formation
Adhesion is influenced by the cells’ ability to form an
extracellular matrix, which acts as a natural substratum for cell
attachment. To test if adhesion inhibitors would influence
extracellular matrix formation, HDF cells were grown in the
presence or absence of 500 nM GST, MAM7, F1 or FnBPA
inhibitors and matrix formation was evaluated visually and
quantitative using fluorescence plate assays. Exogenously
added rhodamine-labeled fibronectin, which gets incorporated
into the cells’ endogenous matrix, was used as a probe for
matrix formation. Cells were visualized by fluorescence
microscopy following 12 and 24 hours of incubation,
respectively (Figure 7). In medium alone (NI), fibronectin
Figure 4.  Adhesion inhibitors do not affect host cell survival.  Cell death of HaCaT (A), HDF (B) or HeLa cells (C) was
measured using lactate dehydrogenase release assays following 4 hours (black) or 24 hours (gray) of incubation in growth medium
alone (NI) or medium containing 500 nM immobilized GST (CB), MAM7, F1 or FnBPA peptide, or 1μM staurosporine (+ control).
Results are means ± standard deviation from one of a set of three experiments done in triplicate. According to student t-test, p<0.01
for all samples compared to positive control.
doi: 10.1371/journal.pone.0081216.g004
Figure 5.  Adhesion inhibitors do not affect host cell proliferation.  Proliferation of HaCaT (A), HDF (B) or HeLa cells (C) was
measured using a CyQUANT NF proliferation assay in medium alone (NI) or medium containing 500 nM immobilized GST (CB),
MAM7, F1 or FnBPA peptides. Results are means ± standard deviation from one of a set of three experiments done in triplicate.
doi: 10.1371/journal.pone.0081216.g005
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fibrillogenesis was apparent after 12 hours, and by 24 hours a
dense meshwork of long fibers had formed (Figure 7A, F).
Similar results were obtained in the presence of control beads
or MAM7 inhibitor (Figure 7b,c,g,h). In contrast, in the presence
of either F1 or FnBPA inhibitors, fibronectin fibers were less
dense, shorter and thinner than in the control (Figure 7D, E, I,
J). Matrix formation was quantified by measuring the amount of
rhodamine-fibronectin incorporated into endogenous fibronectin
fibrils in the presence or absence of inhibitors after 12 and 24
hours, respectively. No significant decrease in fluorescence
was detected between untreated wells and wells containing
either control beads or MAM7 inhibitor at either time point
(Figure 7L). However, the presence of either F1 or FnBPA
inhibitors lead to a decrease of fluorescence levels by
approximately 80 and 90%, respectively, reflecting a decrease
in matrix formation after both 12 and 24 hours (Figure 7L).
Discussion
Many bacterial pathogens rely on fibronectin as a surface
receptor for host attachment, so competitive adhesion inhibitors
based on fibronectin-binding domains derived from bacterial
adhesins have large potential for future use in the management
of bacterial infections. However, fibronectin is a key molecule
mediating a range of cellular processes necessary for wound
healing, such as cell proliferation, adhesion, migration and
matrix formation and thus fibronectin binding by adhesins or
adhesin-derived peptides can interfere with these processes
and potentially lead to undesired side-effects such as delays in
wound healing and aberrant vascular remodeling [10]. To test
for potential side-effects which might be caused by topical
treatment of wounds, we utilized cultured host cells to test an
adhesion inhibitor based on a peptide derived from V.
parahaemolyticus MAM7 for its effect on S. aureus attachment
as well as host cellular functions in vitro. As controls, we
included two adhesion inhibitors based on fibronectin-binding
peptides derived from S. pyogenes F1 and S. aureus FnBPA,
respectively, in our analysis.
We found that all three peptides, when immobilized on
beads, efficiently inhibited adhesion of the methicillin-resistant
S. aureus strain USA300 to host cells at nanomolar
concentrations, demonstrating the potential benefit of such
inhibitors for the treatment of MDR infections. As a first step
towards further development of the MAM7-based inhibitor, we
analyzed its effect and the effect of the two control inhibitors on
host cellular functions. Fibroblasts and keratinocytes are cell
types that play important roles in wound healing. Since we aim
to develop MAM7-based adhesion inhibitors for topical
treatment of wounds, we analyzed host cellular function in
HaCaT and HDF cell lines. As additional control, we tested the
effects on HeLa cells, an unrelated but well characterized cell
type not involved in cutaneous repair.
Both F1 and FnBPA-based inhibitors, although efficient in
preventing bacterial adhesion, caused a delay in wound
healing in tissue culture models (Figures 2, 3). This inhibitory
effect was not due to changes in cell viability or proliferation
caused by the peptides. However, both F1 and FnBPA
inhibitors impaired extracellular matrix formation and cellular
adhesion. This is in agreement with previous studies, which
reported that the F1-derived peptide FUD impairs matrix
formation and, dependent on the peptide concentration, may
impair cellular adhesion [9]. Deposition of soluble fibronectin
into fibrils is one of the initial steps in extracellular matrix
formation and fibronectin fibrils act as a basis for the deposition
of other matrix proteins, such as collagen, fibrinogen and fibulin
[25-27]. Accumulation of fibronectin is dependent on the
interaction of soluble fibronectin and adherent cells, which
causes a conformational change in fibronectin that is
necessary for fibrillogenesis [28]. High-affinity bacterial
fibronectin-binding peptides, but not the lower affinity ligand
MAM7, interfere with both soluble and deposited fibronectin
assembly, thus blocking one of the fundamental steps in the
healing process. Formation of extracellular matrix in turn is a
prerequisite for cellular adhesion and this explains why
inhibition of matrix formation by F1 and FnBPA-based inhibitors
resulted in a significant decrease of cellular adhesion [29].
Taken together, impairment of these two steps is sufficient to
Figure 6.  Effect adhesion inhibitors on host cellular adhesion in the presence of serum.  Adhesion of HaCaT (A), HDF (B) or
HeLa cells (C) to culture vessels was measured following 2 hours (black) or 12 hours (grey) of incubation in medium containing 10
% FBS alone (NI) or medium containing 500 nM immobilized GST (CB), MAM7, F1 or FnBPA peptide. Results are means ±
standard deviation from one of a set of three experiments done in triplicate. Values significantly different from the control (p<0.01
according to student t-test) are indicated (*).
doi: 10.1371/journal.pone.0081216.g006
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cause delayed migration and thus wound healing and explains
the phenotype observed in in vitro wound healing assays.
In conclusion, our studies suggest there is a trade-off
between high affinity binding to fibronectin and inhibition of
wound healing, which likely precludes most bacterial
fibronectin-binding peptides from being used as anti-adhesion
compounds. Further studies on adhesin-based inhibitors
should take this into account and carefully evaluate the impact
of such inhibitors on cellular function. In contrast to F1 and
FnBPA, MAM7 uses the host cell lipid phosphatidic acid as a
main receptor and its interaction with this lipid species is the
basis for high affinity binding of the adhesin to host cells.
Fibronectin acts as a co-receptor to increase the on-rate of
binding but its interaction with MAM7 is of relatively low affinity
[12]. This synergistic mode of host cell engagement means that
MAM7 based inhibitors stably attach to host cells and are able
to competitively inhibit binding of MRSA, which uses fibronectin
as a receptor, without abrogating fibronectin-mediated host
cellular functions. Thus, its mechanism of receptor binding
suggests MAM7 is a good candidate molecule for the
development of anti-adhesion lead compounds and we will take
the presented results as a basis to progress the development
of these compounds towards testing them in an in vivo wound
healing model.
Supporting Information
Figure S1.  Comparison of different MAM7-based inhibitors
for their efficacy against enteric pathogens. Following
treatment with MAM-based adhesion inhibitors, Hela cells were
infected with V. parahaemolyticus (A), V. cholera (B), Y.
pseudotuberculosis (C) or EPEC (D), as previously described
[11]. Inhibitors consisted either of MAM7 peptide (7) or MAM7
mce1 domain (1) expressed on the surface of E. coli BL21
(bact.), purified recombinant protein (prot) or bead-coupled
protein (bead). As control, cells were treated with BL21
expressing MAM7ΔN1-44 (not surface exposed), GST-tag only
(prot C) or bead-coupled GST-tag (bead C). (+) infected cells
without prior treatment; (-) uninfected cells; LDH release was
measured and drawn as % cell lysis (normalized to 100% =
detergent lysed cells). For EPEC, pedestals per cell were
counted as previously described [11]. Results are means ±
standard deviation from experiments done in triplicate.
(TIF)
Figure S2.  Integrity of anti-adhesion peptide inhibitors
over time. The integrity of MAM7, F1 or FnBPA peptides co-
incubated with fibroblast monolayers was determined using
SDS-PAGE and densitometry. Values are expressed as %
Figure 7.  Influence of adhesion inhibitors on in vitro matrix formation.  Incorporation of rhodamine-labelled fibronectin into the
extracellular matrix of fibroblasts was visualized by fluorescence microscopy, after 12 or 24 hours of incubation in medium alone (NI,
A, F) or medium containing immobilized GST (CB, B, G), MAM7 (C, H), F1 (D, I) or FnBPA (E, J) derived peptides. Background
fluorescence of unlabelled cells at t=0 hours (K). Scale bar, 10 μm. Images are representative of a set of three experiments, with at
least three frames taken per replicate. Incorporation of rhodamine-fibronectin into the extracellular matrix in medium alone (NI) or
medium containing immobilized GST (CB), MAM7, F1 or FnBPA derived peptides was quantified after 12 hours (grey) and 24 hours
(black) incubation using fluorescence plate assays (L). Values significantly different from the control (p<0.01 according to student t-
test) are indicated (*).
doi: 10.1371/journal.pone.0081216.g007
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integrity and results are means ± standard error from three
replicates.
(TIF)
Figure S3.  Effect of adhesion inhibitors on host cellular
adhesion in the absence of serum. Adhesion of HaCaT (a),
HDF (b) or HeLa cells (c) to culture vessels was measured
following 2 hours (black) or 12 hours (grey) of incubation in
serum-free medium alone (no inhibitor, NI) or medium
containing 500 nM bead-immobilized GST (CB), MAM7, F1 or
FnBPA peptide. Results are means ± standard deviation from
one of a set of three experiments done in triplicate. Values
significantly different from the control (p<0.01 according to
student t-test) are indicated (*).
(TIF)
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